BENLYSTA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for BENLYSTA (BENLYSTA).

How it works

Belimumab is a human IgG1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLyS, also known as BAFF), inhibiting its activity. BLyS is a cytokine that promotes B-cell survival and differentiation. By binding BLyS, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.

What the body does with it

Metabolism	Belimumab is a monoclonal antibody and is not metabolized by cytochrome P450 enzymes; clearance is thought to occur via proteolytic degradation.
Excretion	Not extensively characterized; expected to be degraded into small peptides and amino acids via general protein catabolism. Renal and fecal elimination are minor pathways.
Half-life	Terminal half-life approximately 18.6 days (range 13–31 days) in patients with SLE, supporting monthly intravenous dosing.
Protein binding	Approximately 65–70% bound to plasma proteins, primarily immunoglobulins and albumin.
Volume of Distribution	Vd ~ 0.19 L/kg (approximately 13.5 L for a 70 kg adult), indicating limited distribution primarily to the vascular space.
Bioavailability	SC: ~82% relative to IV; IV: 100%.
Onset of Action	IV: Improvement in disease activity observed as early as 4 weeks; SC: Onset similar, with clinical benefit seen by 8 weeks.
Duration of Action	Sustained suppression of disease activity with monthly IV (or weekly SC) dosing; effects persist for several weeks after last dose due to long half-life.

Classification & Brands

Dosing & administration

10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for mild to moderate renal impairment (CrCl >=30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min) or ESRD. Use caution and consider benefit-risk.
Liver impairment	No dedicated studies; however, belimumab is not metabolized by the liver. No dose adjustment recommended based on Child-Pugh class.
Pediatric use	In pediatric patients (>=5 years): IV: 10 mg/kg IV at 2-week intervals for first 3 doses, then 10 mg/kg IV every 4 weeks. SC: 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses). Not approved for children <5 years.
Geriatric use	No specific dose adjustment; select with caution due to greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or drug therapy. Monitor for infections and adverse reactions.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for BENLYSTA (BENLYSTA).

Breastfeeding	No human data on belimumab in breast milk. Belimumab is a large monoclonal antibody likely present in milk at low concentrations. M/P ratio unknown. Developmental benefits of breastfeeding should be weighed against potential infant exposure and risk of immunosuppression.
Teratogenic Risk	First trimester: Based on animal studies, belimumab may cause fetal harm due to known immunomodulatory effects; limited human data. Second trimester: Potential for fetal B-cell depletion as IgG crosses placenta after 13 weeks gestation. Third trimester: IgG actively transported across placenta; risk of neonatal immunosuppression (e.g., prolonged B-cell depletion, increased infection risk).

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

None known; caution in patients with severe active infections.

Clinical Precautions

Precautions	["Hypersensitivity reactions including anaphylaxis","Infusion reactions","Increased risk of serious infections, including tuberculosis and opportunistic infections","Malignancy risk (potential)","Hypogammaglobulinemia","Depression and suicidality"]
Food/Dietary	No known food interactions. May be taken without regard to meals.

Clinical Tips & Counseling

Clinical Pearls

Drug interactions

Loading safety data…

BENLYSTA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for BENLYSTA (BENLYSTA).

How it works

What the body does with it

Metabolism	Belimumab is a monoclonal antibody and is not metabolized by cytochrome P450 enzymes; clearance is thought to occur via proteolytic degradation.
Excretion	Not extensively characterized; expected to be degraded into small peptides and amino acids via general protein catabolism. Renal and fecal elimination are minor pathways.
Half-life	Terminal half-life approximately 18.6 days (range 13–31 days) in patients with SLE, supporting monthly intravenous dosing.
Protein binding	Approximately 65–70% bound to plasma proteins, primarily immunoglobulins and albumin.
Volume of Distribution	Vd ~ 0.19 L/kg (approximately 13.5 L for a 70 kg adult), indicating limited distribution primarily to the vascular space.
Bioavailability	SC: ~82% relative to IV; IV: 100%.
Onset of Action	IV: Improvement in disease activity observed as early as 4 weeks; SC: Onset similar, with clinical benefit seen by 8 weeks.
Duration of Action	Sustained suppression of disease activity with monthly IV (or weekly SC) dosing; effects persist for several weeks after last dose due to long half-life.

Classification & Brands

Dosing & administration

10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for mild to moderate renal impairment (CrCl >=30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min) or ESRD. Use caution and consider benefit-risk.
Liver impairment	No dedicated studies; however, belimumab is not metabolized by the liver. No dose adjustment recommended based on Child-Pugh class.
Pediatric use	In pediatric patients (>=5 years): IV: 10 mg/kg IV at 2-week intervals for first 3 doses, then 10 mg/kg IV every 4 weeks. SC: 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses). Not approved for children <5 years.
Geriatric use	No specific dose adjustment; select with caution due to greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or drug therapy. Monitor for infections and adverse reactions.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for BENLYSTA (BENLYSTA).

Breastfeeding	No human data on belimumab in breast milk. Belimumab is a large monoclonal antibody likely present in milk at low concentrations. M/P ratio unknown. Developmental benefits of breastfeeding should be weighed against potential infant exposure and risk of immunosuppression.
Teratogenic Risk	First trimester: Based on animal studies, belimumab may cause fetal harm due to known immunomodulatory effects; limited human data. Second trimester: Potential for fetal B-cell depletion as IgG crosses placenta after 13 weeks gestation. Third trimester: IgG actively transported across placenta; risk of neonatal immunosuppression (e.g., prolonged B-cell depletion, increased infection risk).

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

None known; caution in patients with severe active infections.

Clinical Precautions

Precautions	["Hypersensitivity reactions including anaphylaxis","Infusion reactions","Increased risk of serious infections, including tuberculosis and opportunistic infections","Malignancy risk (potential)","Hypogammaglobulinemia","Depression and suicidality"]
Food/Dietary	No known food interactions. May be taken without regard to meals.

Clinical Tips & Counseling

Clinical Pearls

Drug interactions

Loading safety data…